Auna is a deeply discounted Latin American healthcare growth platform whose integrated model and Mexican recovery could unlock substantial upside, but leverage and execution make it a high-risk, high-reward investment.
Overview
Auna is a horizontally and vertically integrated healthcare platform operating in underpenetrated Spanish-speaking Latin American markets, with Peru as its mature anchor, Colombia as a high-complexity provider market, and Mexico as the principal growth opportunity. Its 31-facility, 2,337-bed network is focused on high-margin, relatively non-cyclical oncology, cardiology, neurosurgery, and trauma care, while Oncosalud provides recurring plan revenue from more than 1.4 million members. **The core moat is the payor-provider loop**, which supports an oncology MLR of approximately 49.6%–50.1% versus roughly 75% for regional peers. In 2Q26, revenue increased 13.2% to S/1,238 million and beat consensus by approximately 7.5%, but Adjusted EBITDA fell 5.8% to S/227 million and margin declined to 18.4% from 22.1%; adjusted EPS was approximately $0.15 versus $0.26 consensus. The balance sheet remains the principal constraint, with approximately $988 million of net debt, 3.6x leverage, and 1.33x–1.6x interest coverage. At $5.24, valuation is only 0.31x LTM sales and 4.98x forward P/E. Near-term catalysts are Mexican utilization recovery, Colombia and Mexico pricing actions, Torre Trecca, and deleveraging toward below 3.0x.